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Abstract
Dehydroepiandrosterone (DHEA) and its sulfated ester (DHEA-S) are important pre-hormones
that also have direct neurohormonal effects on the central nervous system. Over the last twenty
years, data have revealed that serum DHEA peaks in a person’s mid-20s and steadily declines
throughout their lifetime. In addition, women tend to have lower values than men. This is of note
because lower serum values tend to be correlated with increased risk of depression, worse
depressive symptoms, and increased risk of relapse into depression. A review of literature
concerning DHEA’s age related values, its association with depression, and its use in the
treatment of depression was performed. It was found that supplementation with DHEA appears
to alleviate the symptoms of depression even though a dose-response relationship nor a clear
mechanism have been established. For providers who choose to use DHEA to alleviate the
symptoms of depression, they should consider that even the best studies concerning its
effectiveness are underpowered, it lacks FDA approval, and, if given as a supplement, may lack
any active ingredient. Despite those warnings, the AAPA, CANMAT, and Dynamed all agree
that evidence exists as to its efficacy.
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Dehydroepiandrosterone for Treatment of Depression

4

Introduction
Major depressive disorder, depression, and dysthymia are often overlooked and
undertreated conditions in the primary care field. This exists for a variety of reasons: social
stigma, provider experience, concerns over medication side-effects, and cost of treatment, to
name a few. Considering that in very many cases treatment of depression can be the difference
between life and death for a patient, using every tool available seems imperative.
Dehydroepiandrosterone and its sulphate ester (DHEA(-S)), a physiological marker and predictor
for depression, especially in the elderly, is established despite some conflicting studies. The
purpose of this paper is to ascertain if DHEA supplementation is a viable option for the treatment
of depression in comparison to current standards of treatment with selective serotonin reuptake
inhibitors (SSRIs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs),
especially considering DHEA’s low cost and low side effect profile.
Statement of the Problem
Primary care providers who do choose to treat major depressive disorder, depression, and
dysthymia seem to limit their pharmacological options to only the SSRIs, SNRIs, and other
prescription-only antidepressants. DHEA’s low side effect profile, comparatively low cost, and
availability may make it an ideal adjunct or replacement to current therapy. But is it effective?
Because of DHEA’s known age related decline, this paper will focus on adults only.
Research Questions
For patients older than 30 who have major depression, depressive symptoms, or
depressive episodes, does supplementation with DHEA improve symptoms or lessen episodes of
depression?
Research Methods
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A search of PubMed with search parameters and MeSH terms “DHEA [MAJR] AND
depression [MAJR]” was performed in preparation for this paper. Inclusion criteria were: no
animal studies, no studies that focused on depressive comorbidities, no confounding coadministration of testosterone, and, with the exception of a few foundational studies, only studies
in the last 5 years were included. CINAHL, Clinical Key, Google Scholar, and PsychINFO
searches using similar terms showed no additional new studies. Studies selected for this paper
include meta-analysis; double blind, randomized, placebo-controlled studies; clearing-house
recommendations; and literature reviews.
Review of Literature
DHEA, DHEA-S, Age Related Decline and its Significance in Depression
Dehydroepiandrosterone (DHEA) and its sulfated ester (DHEA-S) are pre-hormones that
are produced by the adrenal glands and can be converted to testosterone or estrogen in the
peripheral tissues. In addition to being converted, DHEA and DHEA-S also appear to have
direct effect in the CNS as neurohormones.
In humans, DHEA and its sulfated ester appear to be low during childhood and increase
beginning around age 5-6 in the process of “adrenarche” (Guran et al., 2015). Guran et al.’s
(2015) data also shows increased amounts of DHEA for boys as compared to girls. For men,
values of DHEA peak in their early 20s (Friedrich et al., 2008). Unlike testosterone, values of
DHEA are not subject to as large of a diurnal variance but do undergo a larger age-related
decline; levels of DHEA in men aged over 75 are roughly one-third the value of those aged 2025. These physiologically reduced levels are associated with specific age-related maladies,
including depression; among elderly populations even lower physiological levels of DHEA
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through “adrenopause” seem to either predict or show greater symptomology of these conditions
(Samaras, Samaras, Frangos, Forster, & Philippe, 2013).
Guran et al.’s (2015) study had a large sample population (N=531) and is sufficiently
powered for our purposes of showing that DHEA increases from birth through adrenarche, there
are differing amounts between boys and girls, and, even though the sample population is all from
Turkey, an assumption about “normal” values can be made.
Picking up where Guran et al. (2015) left off, Friedrich et al. (2008) goes on to show that
DHEA peaks in a man’s early 20’s and then continues to decline throughout his life. Friedrich et
al. (2008) used both linear and quartile regression in a group of 157 German men with both
statistical methods showing age related decline in values. It is of note that mean serum DHEA in
males in the Guran study of 225.76 µg/dL in the over 13 age group is similar to the mean of 286
µg/dL in the males aged 20-24 cohort of the Friedrich data despite the Guran test subjects all
hailing from Turkey and the Friedrich all from Germany.
While Samaras et al.’s (2013) literature review does not offer any specific values of
DHEA that are associated with increased depression, it does offer several studies that indicate
that lower levels are often associated with depression in the elderly and that age related DHEA
decline is the norm.
The data presented previously shows that DHEA begins to climb before age 10, peaks in
one’s mid-20’s, and then proceeds to steadily decline as we age. Age related decline can be
different from person to person, and lower levels across all age spectrums appears to either be
predictive of depression or associated with worse depression. The data supporting lowered
DHEA’s association with depression is complicated with some studies not finding this
correlation and others outright refuting it. The data also hints at a more complicated relationship
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between DHEA and depression involving the body’s response to cortisol whereby even treatment
with more conventional antidepressants can influence the amount of serum DHEA. Specifically,
in those studies where serum DHEA was tested in patients who were being treated with SSRIs,
SNRIs, and tricyclic antidepressants their DHEA was not low compared to a cohort of healthy
individuals. Furthermore, their serum DHEA was not predictive of worse depressive indicators
(Kurita et al., 2013; Morita et al., 2014). This finding was in contrast to the bulk of literature that
found low serum DHEA in a depressed cohort.
The bulk of studies indicate that lower serum DHEA and DHEA-S are associated with
risk of depression (Qiang et al., 2015; Souza-Teodora, Oliveira, Walters, & Carvalho, 2016;
Takehiro et al., 2013; Veronese et al., 2015; Zhu et al., 2015). Kurita et al. (2013) found that
MDD patients who were prescribed psychotropic medications had serum DHEA levels that were
comparably elevated against normal controls. Moreover, Morita et al. (2014) showed depressed,
non-treated subjects had elevated serum DHEA levels that then normalized to a control group of
non-depressed individuals after treatment with SSRIs, SNRIs, and Tricyclics (as appropriate).
Morita also found that those patients whose depression did not remit also continued to show
elevated DHEA levels. In a final study, Moraes, Deslandes, Maciel-Pinheiro, Corrêa, & Laks
(2016) found no correlation between DHEA and depression in their elderly cohort. Qiang et al.’s
(2015) meta-analysis is likely the most comprehensive data to suggest that lowered DHEA is
associated with depression as demonstrated by the following forest plot showing a p value of
0.002 in a study with an N of 10 eligible, case-controlled studies (fig. 1).
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Figure 1: Forest plots for differences between DHEA-S levels in patients with depression and
without.
Qiang, H., Zhang, S., Liu, F., Zhang, Y., Zhu, D., & Zang, Y. (2015). Clinical significance of
decreased protein expression of dehydroepiandrosterone sulfate in the development of
depression: A meta-analysis. Journal of Affective Disorders, 174, 416-423.
https://dx.doi.org/10.1016/j.jad.2014.11.051

Qiang et al. (2015), though, did mention that between the studies selected, it is difficult to assign
specific values to the terms “low” and “high” as it pertains to serum DHEA due to individual
variance. Kurita et al. (2013) and Morita et al. (2014) studies may show differing results than
other papers as their participants were on concurrent antidepressant therapy.
The conflicting data suggest that DHEA’s role in depression is potentially more
complicated than as a single variant and may be more based on the body’s ability to respond to
stress with increased levels of DHEA (Jiang et al., 2017) or be related to a DHEA/Cortisol
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imbalance (Mocking et al., 2015). One potential hypothesis that could account for varied
findings is that increased DHEA and DHEA-S may be the body’s appropriate response to
depression (thusly high DHEA levels are sometimes found in depressed patients) and an inability
to elevate these levels may lead to worse or non-remitting depression (why we may find low
levels as predictive for or during bouts of depression). Though this could be a potential area of
future research, it is beyond the scope of this paper.
Exogenous DHEA in Treating Depression
Bloch, Schmidt, Danaceau, Adams, & Rubinow (1999) was one of the first double blind,
randomized, placebo-controlled studies of the effect of DHEA administration on the effects of
depression. Though statistically significant reductions in depressive indexes as well as in
itemized indicators of depression were demonstrated with promising p values—many at 0.01—
the study is likely underpowered. Because the ANOVA data have been withheld, the effect size
cannot be calculated; however, because this study only has an N of 15 participants, the effect size
to reach a power of 0.8 would need to be quite large. Bloch et al.’s colleagues Schmidt et al.
(2005) attempted to recreate and expound on some of the findings of Bloch et al. with larger N
and with varying doses. Schmidt et al.’s study found similar confidence values in their doubleblind, randomized, placebo-controlled study across indicators and indexes of depression; though,
this time with an N of 46, the power of successive studies are growing. Differing in Schmidt et
al.’s study were doses increasing up to 450 mg with washout periods in between. Finding a dose
response relationship between DHEA and depression would have further cemented DHEA’s
effectiveness in treating depression; however, this link was not established. It is not until Piexto,
Cheda, Nardi, Veras, & Cardoso (2014) that we see a meta-analysis of many of the existing,
albeit underpowered, deliver consistent results. Though Piexto et al. (2014) did not attempt to
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group studies providing a single large N value due to differing methodologies between studies,
the consistency of results is beginning to suggest that DHEA is effective in the treatment of
depression despite all studies being likely underpowered (fig. 2).

Figure 2: Meta-analysis results of exogenous DHEA administration in depressed populations.
Peixoto, C., Cheda, J., Nardi, A., Veras, A., & Cardoso, A. (2014). The effects of
dehydroepiandrosterone (DHEA) in the treatment of depression and depressive
symptoms in other psychiatric and medical illnesses: A systematic review. Current
Drug Targets, 15, 901-914. https://dx.doi.org/10.2174/1389450115666140717111116

What the literature is lacking are larger N studies with enough predictive power to
conclusively say that exogenous DHEA is effective in the treatment of depression. These larger
studies will also be essential if a dose-response relationship is to be discovered.
Comparisons of DHEA to SSRI/SNRIs
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If DHEA is to be seriously considered in the treatment of depression, it must be
compared to SSRIs and SNRIs, the current first-line treatment of depression. In comparison of
DHEA to SSRIs/SNRIs I have considered their efficacy, cost, and side effect profile.
Dynamed’s (2018) interpretation of the literature concerning the treatment of depression
with supplemental DHEA places it as “level 2 (mid-level) evidence” in the treatment of
depression. Interestingly enough SSRIs, SNRIs, counseling, and even St. John’s Wort all carry a
“level 2 (mid-level) evidence” rating concerning their efficacy in the remission of depressive
symptoms.
According to www.goodrx.com, prices for prescription DHEA offer no cost benefits from
the most common and popular anti-depressants: Fluoxetine, Sertraline, and Escitalopram.
Though, there are a few newer antidepressants such as Viibryd that DHEA is significantly
cheaper by comparison.
Many of the side effects of DHEA can be linked to raised testosterone levels (Rosenthal
& Burchum 2018): hirsutism, deepening voice, unfavorable cholesterol profile. Because DHEA
is also a precursor for estrogen, some of the potential side effects also may mimic those of
exogenous estrogen: breast development, shrunken testicles, reduced sperm production. Some
side effects of DHEA are due to its direct CNS effects, mania for instance. Some of the well
documented side effects of SSRIs/SNRIs include dizziness, insomnia, dry mouth, and impotence.
Note that while SSRIs/and SNRIs both carry a black box warning concerning an increased risk
of suicide and DHEA does not, it may be beneficial to not take that into consideration until
further studies have been done, as will be discussed in Clinical Applications.
Discussion
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The presented data seem conclusive about the life-span and gender changes of DHEA
and DHEA-S—that DHEA declines with age after peaking in our twenties, and typically men
have more serum DHEA than women. However, attempts to correlate the existing data to
depression, risk of depression, severity of symptoms, and remission of symptoms are less clear.
Though, a trend among many smaller, under-powered studies is emerging: i.e. that lower DHEA
is associated with risk of depression in the elderly, that a lower DHEA response to depression is
associated with worse, or intractable depression, that higher levels of DHEA are protective
against, or might signal remission of depression.
Data might suggest a mechanism to hormonally correct depression by raising levels of
DHEA (accounting for why some studies show higher levels of DHEA with depression), but that
impairment by physiologically low levels of DHEA, or low levels due to advanced age, might
hinder this mechanism. Bolstering this idea is evidence that when depression is treated even with
SSRIs and SNRIs, serum DHEA rises (Hough et al., 2017). The limits of this response appear to
be personal and highly variable as no dose response mechanism for DHEA and depression has
been identified by the literature. Specifically, Bloch et al. (1999) and Schmidt et al. (2005) found
no increasing benefits with doses as high as 450 mg, whereas other studies only tested—and had
success with—doses as high as 90 mg.
There exists a similarity of rating of evidence between SSRIs, SNRIs, DHEA and St.
John’s Wort according to Dynamed (2018). Note that this does not necessarily imply similar
efficacies, only that they have similar evidences that they are at all efficacious. I interpret this as
meaning that treatment of depression is often multi-faceted and it is not entirely clear at the
outset of treatment, to which treatment methodology someone will respond.
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Though the studies concerning the treatment of depression with exogenous DHEA are
double-blind, randomized, placebo-controlled studies, they are all hindered by low power. As
mentioned before, larger studies are needed to confirm what many well-designed though lowpowered studies are starting to suggest.
Clinical Application
There is agreement among AAPA (Slawson, 2005), CANMAT (Ravindran et al., 2016),
and Dynamed (2018) that exogenous DHEA may be useful in the treatment of depression.
However, the lack of powerful studies in the data leaves us with a few questions yet about its
best practice use. What dose does the literature support? What serum level is important? Is it
effective only as a sole agent? Are its side effects acceptable?
Because there has yet to be a dose-response relationship established, starting with the
lowest tested dose—30 mg—and titrating up to the largest dose—400 mg (Piexto et al. 2014)—
is reasonable. Indeed, because of the lack of dose-response relationship any, even the lowest,
prescription of DHEA might prove effective. Furthermore, because of a lack of a dose-response
relationship, in DHEA therapy for depression we are not attempting to achieve an effective
serum level and if symptomatic alleviation is our goal, serum testing is moot. At least one study
(Hough et al., 2018) has recommended that DHEA might be efficacious as co-therapy for
treatment of depression.
DHEA is not without side effects. Though, at least its side effect profile is different from
those of the SSRI/SNRIs, offering a patient options to current du jour treatments. Whereas
SSRI’s and SNRI’s side effect profile is centered largely around neurological and serotonin
dysfunction, DHEA’s side effects are centered around its role as a precursor hormone to both
testosterone and estrogen. It should be noted that even though DHEA does not carry a black box
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warning of risk of suicide, the prudent caregiver will proceed as though it does as at least one
proposed mechanism for risk of suicide with antidepressant therapy is the increased self-efficacy
that accompanies reduced depression.
With all of this in mind, best practice for prescriptions of DHEA might include
prescribing as a sole agent for mild to moderate depression or when the patient finds the side
effects of other therapy intolerable. Its use as a sole agent might be more effective in elderly
men. It could be prescribed as co-therapy with more traditional antidepressants. Above all,
treatment with DHEA should be done so with its particular side effects in mind, as well as the
added risk of increased suicidality. Also of key clinical importance is DHEA’s lack of FDA
approval for the treatment of depression, meaning every provider who prescribes DHEA for
depression should be prepared to plainly state why they did not treat with FDA approved drugs.
Finally, if a provider chooses to treat depression with DHEA they should note that while it is
available over the counter as a supplement, only pharmaceutical DHEA is sure to contain
DHEA; supplements routinely fail to demonstrate they contain any claimed active ingredient.
With this in mind, the aim of this paper was to provide another tool for the primary care provider
to manage the sometimes life-threatening scourge of depression.
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